Ioana Coțofană1, Roxana Roșca1,2, Alexandra Mirică1, M. Coțofană3, F. Codresi1, A. L. Goldstein1, D. N. Păduraru3,2, R. Mirică5, S. Păun4,2, Diana Loreta Păun1,2
1“C.I. Parhon” National Institute of Endocrinology
2“Carol Davila” University of Medicine and Pharmacy
3Bucharest University Emergency Hospital, Romania
4Bucharest Emergency Hospital, Romania
5“Sf. Ioan” Clinical Emergency Hospital, Bucharest, Romania
Corresponding author: Dan Nicolae Păduraru
Phone no. 0040744756443
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


Primary ovarian carcinoid tumours are rare neoplasms. Carcinoid tumours mostly occur in the gastrointestinal tract and the lungs. Ovarian carcinoid tumours constitute only 0.5% of all carcinoid tumours and <0.1% of all ovarian carcinomas. Conventional tumour pathology criteria and DNA cytometry have limited value in assessing the malignancy of a neuroendocrine tumour. Hence, the detection of substances that are more specific for carcinoid tumours can facilitate a more exact diagnosis. Two markers are primarily used to diagnose and follow carcinoid tumours: 5-hydroxyindoleacetic acid (5-HIAA) and chromogranin A (CgA).We present the case of a 35-year-old female without personal pathological antecedents, diagnosed with right ovarian tumour at an ultrasound examination, without any clinical symptoms, for which she underwent right ovarectomy in January 2015, with histopathological diagnosis of stromal carcinoid (well differentiated neuroendocrine tumour) and immunohistological result of well differentiated G1 ovarian tumour. At present, the patient is under periodical endocrinological monitorization. 5-hydroxyindoleacetic acid, serotonin and chromogranin A levels are in normal ranges currently. Preoperatively there was no endocrinological evaluation or specific blood test examination with biochemical markers.

Keywords: ovarian carcinoid tumour, neuroendocrine tumour

Sunday the 18th.